Collegium Poised To Re-Launch Nasal Spray As AllerNase In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is also working on reformulations of Forest/Cypress’ investigational serotonin-norepinephrine reuptake inhibitor milnacipran in Phase III development for treatment of fibromyalgia.
You may also be interested in...
Accentia Chronic Sinusitis Candidate Fails Phase III Clinical Study
Disappointing trial data for intranasal lavage formulation sends Florida firm’s stock price tumbling by more than two-thirds.
Accentia Chronic Sinusitis Candidate Fails Phase III Clinical Study
Disappointing trial data for intranasal lavage formulation sends Florida firm’s stock price tumbling by more than two-thirds.
GSK’s Veramyst To Launch By Late May
Flonase follow-on is indicated for treatment of seasonal and perennial allergic rhinitis in adults and children two years of age and older.